Eltrekibart Biosimilar - Research Grade

Human

CXCL

>1mg/ml

IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P19875;P19876;Q07325

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of eltrekibart, a human IgG4-kappa antibody built around the ELR+ CXC chemokine ligands of CXCR1/CXCR2. It reproduces the antigen-binding activity of the originator biologic for laboratory use only and is not the clinical drug; it is not for human or veterinary use. Because the originator is described as a "septa-specific" antibody that recognizes a shared epitope across the ELR+ chemokines, this analog is useful as a defined, reproducible tool for probing chemokine neutralization, competitive binding, and epitope-mapping workflows. Typical research applications include positive/isotype-matched controls, ligand-neutralization and receptor-signaling assays, ELISA/SPR/BLI binding characterization, and as a benchmarking reagent in biosimilarity or antibody-engineering programs. It is supplied at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), as an in-vivo-standard-format material, and in bulk milligram-to-gram quantities to support screening, assay development, and preclinical model work. Format is unconjugated to preserve flexibility for downstream labeling or assay design. The ELR+ CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8/IL-8) share the Glu-Leu-Arg (ELR) motif preceding the first cysteine and signal through the G-protein-coupled receptors CXCR1 and CXCR2. They are potent chemoattractants for neutrophils and other myeloid cells and drive angiogenesis, wound repair, and inflammatory amplification. Their expression is induced by pro-inflammatory stimuli (IL-1, TNF, bacterial products), and sustained signaling is implicated in inflammatory and autoimmune conditions and in tumor microenvironments. By contrast, ELR-negative CXC chemokines such as CXCL9, CXCL10, and CXCL11 signal mainly through CXCR3, recruit activated T cells and NK cells, and are angiostatic rather than angiogenic. Blocking the shared ELR+ ligand pool limits combined CXCR1/CXCR2-mediated neutrophil recruitment without necessarily affecting the CXCR3 axis.

Growth-regulated protein beta, Gro-beta, Macrophage inflammatory protein 2-alpha, MIP2-alpha, GRO-gamma(1-73), Growth-regulated protein gamma, GRO-gamma, Macrophage inflammatory protein 2-beta, MIP2-beta, Gamma-interferon-induced monokine, Monokine induce

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Eltrekibart (anti-CXCL) Biosimilar

Q: Is the Eltrekibart biosimilar available in bulk or gram quantities?

A: Yes — the Eltrekibart biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Eltrekibart suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Eltrekibart biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Eltrekibart that binds CXCL.